General News Archives

Thursday, September 21st, 2017

CONTINUUS awarded SBIR Phase IIB grant from the National Science Foundation

CONTINUUS Pharmaceuticals was awarded a Phase IIB SBIR grant from the National Science Foundation to accelerate technical development and commercialization of its ICM technology platform. The grant consists of $500,000 over a two year extension period, which increases the total…
Tuesday, June 13th, 2017

CONTINUUS Team meets FDA

The CONTINUUS Team has met with key FDA representatives for a progress update on the implementation of our end-to-end Integrated Continuous Manufacturing (ICM) process.  The picture below includes (from the left) Sap Chattopadhyay, Stephen Born, Salvatore Mascia, Bayan Takizawa, Vida…
Wednesday, February 1st, 2017

CONTINUUS Pharmaceuticals Awarded Best Italian Start-up

On January 9th, 2017 CONTINUUS CEO, Salvatore Mascia, was awarded a price for the 2017 Best Italian Start-Up abroad founded by an Italian entrepreneur.  The picture shows Salvatore receiving the award by the Italian Minister of Foreign Affairs, Angelino Alfano.…
Thursday, January 26th, 2017

CONTINUUS Pharmaceuticals enjoys successful 2016, looking forward to 2017

2016 marked a very successful year for CONTINUUS Pharmaceuticals.  The team was able to advance its innovative technology platform through work done with the National Science Foundation, as well as projects with commercial partners.  As a result, CONTINUUS was able…
Wednesday, December 28th, 2016

The Benefits of Continuous Manufacturing

CONTINUUS was featured on R&D Magazine in an exclusive Q&A with CONTINUUS Pharmaceuticals on continuous manufacturing operational best practices and trends for 2017.…
Wednesday, November 16th, 2016

CONTINUUS Pharmaceuticals Awarded $4.4 M Contract with US FDA

CONTINUUS Pharmaceuticals, Inc. was recently awarded a $4.4 M contract by the US Food and Drug Administration (US FDA).  The purpose of this collaborative work, entitled “Advancement of Integrated Continuous Manufacturing (ICM) Unit Operations,” is to develop a science and…
Tuesday, March 1st, 2016

CONTINUUS awarded SBIR Phase II grant from the National Science Foundation

CONTINUUS Pharmaceuticals was awarded a Phase II SBIR grant from the National Science Foundation to further develop its breakthrough ICM technology. This Phase II grant consists of $750,000 over a two year period, with the opportunity for additional matching funds…
Tuesday, November 3rd, 2015

CONTINUUS secures an additional contract for a top-selling generic medication

CONTINUUS Pharmaceuticals expanded its pipeline by securing a contract with a major pharmaceutical client. CONTINUUS will implement its innovative ICM technology platform for a top-selling generic pharmaceutical.  “This represents a great opportunity for generic pharmaceutical companies. Implementing ICM will allow…
Tuesday, June 16th, 2015

CONTINUUS Pharmaceuticals Presents at 2015 Annual BIO International Convention

CONTINUUS Pharmaceuticals presented its technology platform and product offerings at the 2015 BIO International Convention in Philadelphia on June 16.  CONTINUUS was one of only twelve companies selected by the National Science Foundation to be featured in the Company Presentations…
Monday, May 4th, 2015

MIT-Novartis spinout CONTINUUS Pharmaceuticals lands in Woburn

CONTINUUS was featured in the Boston Business Journal, click here to learn more.…
Thursday, April 23rd, 2015

CONTINUUS to present at the NSF/NIH Bio Innovation Zone during the 2015 BIO International Convention, June 15-18

CONTINUUS Pharmaceuticals was selected to present its technology at the 2015 BIO International Convention in Philadelphia during June 15-18.  CONTINUUS will showcase its work at the NSF/NIH Bio Innovation Zone, which has been funded by a Phase I SBIR grant…
Friday, April 10th, 2015

CONTINUUS Pharmaceuticals celebrates opening of new facility in Woburn, MA

CONTINUUS Pharmaceuticals hosted a ribbon-cutting ceremony to celebrate its new facility in Woburn, MA on April 10, 2015.  A number of industry and government representatives were in attendance, including CONTINUUS’s strategic partners:  I.M.A. Industria Macchine Automatiche, an Italian-based company, global…
Monday, January 12th, 2015

CONTINUUS awarded SBIR Phase I grant from the National Science Foundation

CONTINUUS Pharmaceuticals was awarded a Phase I SBIR grant from the National Science Foundation to further develop its breakthrough ICM technology. This Phase I grant consists of $150,000 over a six month period.…
Thursday, November 6th, 2014

CONTINUUS Partners with New England Controls to Implement Breakthrough Continuous Manufacturing Technology for Pharmaceuticals

Mansfield, MA (November 6, 2014): New England Controls announced a new partnership agreement with CONTINUUS Pharmaceuticals, a revolutionary spin-out company from the Massachusetts Institute of Technology (MIT). This agreement will create a path for CONTINUUS to bring their Integrated Continuous…
Monday, October 27th, 2014

Timothy F. Jamison to join CONTINUUS Advisory Board

CONTINUUS Pharmaceuticals is proud to announce that Timothy F. Jamison, Professor of Chemistry at MIT, will join its Board of Advisors. Prof. Jamison is a world renowned expert in continuous flow chemistry and is involved as a principal investigator at…
Monday, June 9th, 2014

CONTINUUS closes $2 M Series A Financing and establishes a strategic partnership with I.M.A. Industria Macchine Automatiche

On June 9, 2014, CONTINUUS Pharmaceuticals closed its Series A financing round of $2 M, increasing the total capital raised to over $2.4 M.  The round was led by CONTINUUS’s new strategic partner I.M.A. Industria Macchine Automatiche. I.M.A. is a…
Wednesday, February 12th, 2014

CONTINUUS receives an additional seed investment, taking the company to a total capitalization of $395,000

Tuesday, October 1st, 2013

Jonathan Fleming and Tom Van Laar to join CONTINUUS Pharmaceuticals advisory board

CONTINUUS Pharmaceuticals is proud to announce two new members of its advisory board.  Jonathan Fleming is the Managing Partner of Oxford Bioscience Partners, and Tom Van Laar is the Former Head of Global Technical Operation at Novartis Pharmaceuticals. More information…
Wednesday, May 1st, 2013

CONTINUUS receives 265K in seed funding

CONTINUUS Pharmaceuticals completed its first seed financing…
Monday, April 15th, 2013

Semifinalist MIT 100K Competition

CONTINUUS was among the 2013 MIT $100K LAUNCH contest semifinalists…